{
    "clinical_study": {
        "@rank": "65479", 
        "arm_group": {
            "arm_group_label": "SAR245408 polymorph E tablets", 
            "arm_group_type": "Experimental", 
            "description": "Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      - To assess the safety, tolerability and plasma pharmacokinetics (PK) of SAR245408 given\n      once daily as a tablet formulation of polymorph E in subjects with solid tumors or lymphoma.\n\n      Secondary Objectives:\n\n        -  To evaluate the pharmacodynamic (PD) effect of SAR245408 given once daily as a tablet\n           formulation of polymorph E in subjects with solid tumors or lymphoma.\n\n        -  To explore the antitumor activity of SAR245408 given once daily as a tablet formulation\n           of polymorph E in subjects with solid tumors or lymphoma."
        }, 
        "brief_title": "A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasm Malignant", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Screening: 1 to 28 days Study treatment period: two 28-day cycles (56 days) End-of-treatment\n      visit: no later than 7 days after the last study drug administration Subjects not eligible\n      for treatment continuation after Cycle 2 will be followed up for safety; a follow-up visit\n      will be performed within 30 \u00b1 3 days after the last study drug administration Subjects\n      eligible for treatment continuation after Cycle 2 will be offered the opportunity to enroll\n      in the treatment-extension study TED12414.\n\n      Total duration of study participation for each patient: 58 to 118 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Solid tumor that is metastatic or unresectable, or relapsed or refractory lymphoma\n             (including chronic lymphocytic leukemia/small lymphocytic lymphoma), for which\n             standard therapies are no longer effective or there are no therapies known to prolong\n             survival or patient cannot tolerate or has contra-indication for a standard therapy\n             and there is no alternative therapies.\n\n          -  Male or female patient > or = 18 years old.\n\n          -  Weight > or = 40 kg.\n\n          -  Eastern Cooperative Oncology Group performance status < or = 1.\n\n          -  Adequate white blood cells, platelets, and haemoglobin.\n\n          -  Adequate liver and kidney functions.\n\n          -  Fasting plasma glucose < 8.9 mmol/L.\n\n          -  Sexually active patients using adequate contraception.\n\n          -  Women of child-bearing potential with negative pregnancy test.\n\n        Exclusion criteria:\n\n          -  Lymphoma involving the gastrointestinal tract.\n\n          -  Prior treatment with cytotoxic chemotherapy (including investigational agents) or\n             biologic agents (antibodies, immune modulators, and cytokines) within 4 weeks, or\n             nitrosoureas or mitomycin C within 6 weeks, before the first dose of study drug.\n\n          -  Prior treatment with a small-molecule kinase inhibitor (including investigational\n             agents) within 2 weeks, or 5 half lives of the drug or active metabolites, whichever\n             is longer, before the first dose of study drug.\n\n          -  Any other investigational therapy within 4 weeks before the first dose of study drug.\n\n          -  Intolerance to prior treatment with a PI3K inhibitor.\n\n          -  Prior anticancer hormonal therapy within 2 weeks before the first dose of study drug.\n\n          -  Prior radiation therapy within 2 weeks before the first dose of study drug.\n\n          -  Uncontrolled brain metastases or primary brain tumor.\n\n          -  Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus\n             (HIV) infection.\n\n          -  Positive serologies for Hepatitis B surface antigen (HBsAg) or anti-Hepatitis C virus\n             (anti-HCV) antibodies.\n\n          -  Patient is pregnant or breastfeeding.\n\n          -  History of gastrointestinal surgery, or presence of gastrointestinal abnormality or\n             disease, that may affect the pharmacokinetics of study drug.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943838", 
            "org_study_id": "TED12863", 
            "secondary_id": [
                "2012-003368-39", 
                "U1111-1132-9056"
            ]
        }, 
        "intervention": {
            "arm_group_label": "SAR245408 polymorph E tablets", 
            "description": "Pharmaceutical form: tablet Route of administration: oral", 
            "intervention_name": "SAR245408", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "3000"
                }, 
                "name": "Investigational Site Number 056001"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245408 Polymorph E Administered Once Daily to Subjects With Solid Tumors or Lymphoma", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Dose Limiting Toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943838"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From first dose of SAR245408 up to 30 days after the last dose"
            }, 
            {
                "measure": "Maximum SAR245408 plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 8, 15, 29 and 30"
            }, 
            {
                "measure": "Area under the SAR245408 plasma concentration versus time curve", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 8, 15, 29 and 30"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}